Day One Biopharma Expands to ADCs with $55M Drug Acquisition by Lilu Anderson 19.06.2024 "Day One Biopharmaceuticals enhances pipeline, acquiring global rights to promising PTK7-targeting cancer drug DAY301, begins trial soon."
Gilead’s $4.3B Bet on CymaBay’s Liver Drug by Mark Eisenberg 12.02.2024 Gilead Sciences plans to acquire CymaBay Therapeutics for $4.3 billion, expanding their liver disease portfolio. The deal is expected to ...
Gilead Acquires CymaBay: Liver Cure Leap? by Mark Eisenberg 12.02.2024 Gilead Sciences acquires CymaBay Therapeutics for $4.3 billion to expand its liver disease portfolio, including access to potential treatment for ...